Cancer ALK Inhibitor Market, By Drug (Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena)), By Type (First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Anaplastic lymphoma kinase is linked with lung cancer and it may be spread to lymph nodes or other organs in the body, such as brain. Metastases is spreading of cancer cell from one organ to another and lung cancer are mainly of two types i.e. small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC) and it accounts for about 85% of all lung cancers. NSCLC are relatively insensitive to chemotherapy compared to small-cell carcinoma. They are primarily treated by surgical resection with curative intent, although chemotherapy is increasing for both preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy). These types of NSCLC are squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma. According to Nurse’s Health Study, relative risk of SCC is around 5.5, both among smokers compared with non-smoker.Cancer ALK Inhibitor Market accounted for US$ 1.5 billion in 2020 and is estimated to be US$ 10.6 billion by 2030 and is anticipated to register a CAGR of 22.0%

Impact of Covid-19 pandemic on market

Manufacturing facilities were closed due to worldwide lockdown which delays the growth of the market. Reduced hospital visits and treatment seeking rate due to Covid-19 also hampers the overall market of Androgen receptor inhibitor.

Increasing prevalence of Lung cancer

Increasing prevalence of Lung cancer is expected to increase the demand for global androgen receptor inhibitor. Changing lifestyles and other activities like smoking etc. is expected to boost the market for inhibitor demands during forecast period.

Advancement in technology

Cancer patients are looking forward for some advancement in drugs. Further, a large number of companies are now investing into oncology markets to meet the needs of cancer patients. Such companies are contributing for introduction of new drugs with better functionality into market.

Side effects & Unreliable Efficacy

There are many side effects involved in the treatment of this disease. The most common side effect is neutropenia which is temporary and dose-dependent with the white blood count usually return when dose is interrupted or dose is reduce.

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

Source: Prophecy Market Insights

The Global Cancer ALK Inhibitor Market is segmented based on Drug, type, distribution channel and region.

By Drug, the Global Cancer ALK Inhibitor Market is segmented into Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena). By Type, the market is segmented in First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors. By Distribution Channel, the Global Cancer ALK Inhibitor Market is segmented into Hospital pharmacies, Online Pharmacies and Others. By region, the Global Cancer ALK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

Regional Insights:

On region the Global Cancer ALK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market of Androgen Receptor Inhibitor due to increasing rate of development and commercialization of this inhibitor. Asia-Pacific is expected to be highest growth rate with rising patient population and increasing number of domestic players.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Cancer ALK Inhibitor Market report based on drug, type, distribution channel and region.

Global Cancer ALK Inhibitor Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the Global Cancer ALK Inhibitor Market includes AstraZeneca Plc Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc. and Xcovery. Companies are continuously rising the production and supply of drug to the

• Turning Point Therapeutics Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AstraZeneca Plc
• Betta Pharmaceuticals Co. Ltd.
• Bio-Techne Corp.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd
• Xcovery

 “*” marked represents similar segmentation in other categories in the respective section